Scherer, Marcus N. and Graeb, C. and Knechtle, Stuart J. and Jauch, Karl-Walter and Geissler, Edward K. (1999) Use of a soluble RT1A(a)/IgG chimeric molecule to prevent the cytotoxic effects of preformed anti-donor antibodies. LANGENBECKS ARCHIVES OF SURGERY. pp. 423-426. ISSN 1435-2443,
Full text not available from this repository. (Request a copy)Abstract
Background: Currently there is no reliable treatment for hyperacute rejection in presensitized patients. The problem with transplanting an organ to a recipient with preformed anti-donor antibodies is that the organ is at a high risk for destruction via complement-mediated cell cytotoxicity. Unfortunately, the list of presensitized patients is growing, since relatively long or indefinite waiting periods for a compatible organ are common. Methods: To address this problem we have initiated experiments in the rat system to attempt to block anti-donor antibodies with a genetically engineered soluble chimeric MHC class I/IgG molecule. The divalent rat MHC class I-like molecule consists of RT1.A(a) extracellular domains (alpha 1 - alpha 3) bound to each of the two variable regions of an intact IgG1 heavy-chain. Restults: Here we show, using complement-mediated cell cytotoxicity assays, that nanomolar concentrations of purified soluble RT1.A(a)/IgG chimeric molecules were able to greatly reduce the cytotoxic effects of serum containing high concentrations of anti-RT1.A(a) antibody. Conclusions: These results suggest that chimeric MHC class I/IgG molecules may be potentially useful to neutralize the damaging effects of anti-donor antibody in presensitized recipients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Nov 2022 09:53 |
| Last Modified: | 30 Nov 2022 09:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48688 |
Actions (login required)
 |
View Item |
